Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Reversal of vascular leak with imatinib.

Aman J, Peters MJ, Weenink C, van Nieuw Amerongen GP, Vonk Noordegraaf A.

Am J Respir Crit Care Med. 2013 Nov 1;188(9):1171-3. doi: 10.1164/rccm.201301-0136LE. No abstract available.

PMID:
24180451
2.

Reversal of vascular leak with imatinib: a role for IL-2?

Shin JI, Eisenhut M.

Am J Respir Crit Care Med. 2014 Jul 1;190(1):117-8. doi: 10.1164/rccm.201402-0299LE. No abstract available.

PMID:
24983224
3.

Reply: Reversal of vascular leak with imatinib: a role for IL-2?

van Nieuw Amerongen GP, Aman J, Vonk Noordegraaf A.

Am J Respir Crit Care Med. 2014 Jul 1;190(1):118. doi: 10.1164/rccm.201403-0545LE. No abstract available.

PMID:
24983225
4.

Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?

Erre GL, Pardini S, Cuccuru L, Taras L, Passiu G.

Joint Bone Spine. 2015 Jan;82(1):72-3. doi: 10.1016/j.jbspin.2014.06.004. Epub 2014 Jul 22. No abstract available.

PMID:
25059880
5.

[Imatinib for pulmonary arterial hypertension].

Hoeper MM, Opitz C, Olschewski H, Ulrich S, Speich R, Behr J, Halank M, Wilkens H, Klose H, Lange TJ, Grünig E, Seeger W, Ewert R, Borst MM, Welte T, Rosenkranz S, Ghofrani HA.

Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S151-4. doi: 10.1055/s-0034-1387457. Epub 2014 Dec 9. Review. German. No abstract available.

PMID:
25489685
6.

[Treatment with imatinib for refractory PAH].

Nakamura K, Akagi S, Sarashina T, Ogawa A, Matsubara H, Ito H.

Nihon Yakurigaku Zasshi. 2014 Apr;143(4):173-7. Review. Japanese. No abstract available.

PMID:
24717604
7.

Imatinib-induced bone edema: case report and review of literature.

dos Santos LV, Lima JP, Abdalla KC, Bragagnoli AC, Santos FA, dos Anjos Jácome A, Porto FE.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1187-91. Review.

PMID:
24142819
8.

Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?

Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, Cabane J.

Rheumatology (Oxford). 2014 Feb;53(2):378-9. doi: 10.1093/rheumatology/ket261. Epub 2013 Jul 27. No abstract available.

9.

EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.

Bonifacio M, Binotto G, Calistri E, Maino E, Tiribelli M; Gruppo Triveneto LMC.

Ann Hematol. 2014 Jan;93(1):163-4. doi: 10.1007/s00277-013-1974-z. Epub 2013 Nov 29. No abstract available.

PMID:
24292539
10.

Imatinib in neurofibromatosis type 2.

Lim S, de Souza P.

BMJ Case Rep. 2013 Jul 8;2013. pii: bcr2013010274. doi: 10.1136/bcr-2013-010274.

11.

Bone metabolism during long-term treatment with imatinib.

O'Sullivan S, Horne A, Wattie D, Porteous F, Gamble G, Browett P, Grey A.

Leuk Lymphoma. 2013 Aug;54(8):1783-5. doi: 10.3109/10428194.2012.760734. Epub 2013 Jan 24. No abstract available.

PMID:
23278638
12.

Management of the new patient with CML in chronic phase.

Marin D.

Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0. Review.

PMID:
23381448
13.

Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.

Levitzki A.

Annu Rev Pharmacol Toxicol. 2013;53:161-85. doi: 10.1146/annurev-pharmtox-011112-140341. Epub 2012 Oct 8. Review.

PMID:
23043437
14.

Imatinib for the treatment of rheumatic diseases.

Paniagua RT, Robinson WH.

Nat Clin Pract Rheumatol. 2007 Apr;3(4):190-1. No abstract available.

PMID:
17396105
15.

Ventricular interdependence in pulmonary arterial hypertension: providing small pieces of a complex puzzle.

Gorter TM, Willems TP, van Melle JP.

Eur J Heart Fail. 2015 Jan;17(1):1-2. doi: 10.1002/ejhf.195. No abstract available.

16.

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

Helbig G, Kyrcz-Krzemień S.

Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15. No abstract available.

17.

Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.

Wicherts DA, van Coevorden F, Klomp HM, van Huizum MA, Kerst JM, Haas RL, van Boven HH, van der Hage JA.

World J Surg Oncol. 2013 Mar 8;11:59. doi: 10.1186/1477-7819-11-59.

18.

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.

Bouchet S, Dulucq S, Pasquet JM, Lagarde V, Molimard M, Mahon FX.

Leukemia. 2013 Aug;27(8):1757-9. doi: 10.1038/leu.2013.13. Epub 2013 Jan 16. No abstract available.

PMID:
23392357
19.

[Chronic myelogenous leukemia: management of treatment-related adverse events].

Takahashi N.

Rinsho Ketsueki. 2012 Oct;53(10):1581-8. Review. Japanese. No abstract available.

PMID:
23037730
20.

Management of gastrointestinal stromal tumor: the imatinib era and beyond.

Parikh PM, Gupta S.

Indian J Cancer. 2013 Jan-Mar;50(1):31-40. doi: 10.4103/0019-509X.112289. Review.

Items per page

Supplemental Content

Write to the Help Desk